[Skip to Content]
[Skip to Content Landing]
Correspondence
December 15, 2008

Eczematous Dermatitis in the Setting of Hyper-IgE Syndrome Successfully Treated With Omalizumab

Arch Dermatol. 2008;144(12):1662-1663. doi:10.1001/archdermatol.2008.510

Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency (<1 case per million population) characterized by elevated serum IgE levels, recurring staphylococcal skin abscesses, and pneumonias.1 Patients with HIES may show peripheral eosinophilia, eosinophilic infiltration of the skin, and increased susceptibility to infection.2 In newborns, it first manifests as an eruption3 that usually persists as a moderate to severe eczematoid dermatitis into childhood and adulthood. This multisystem disorder is associated with skeletal, facial, and dental abnormalities.1 We report the first case to our knowledge of a patient with HIES with severe recalcitrant eczematous dermatitis successfully treated with high-dose monoclonal anti-IgE therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×